AbbVie picks first Alzheimer's, Parkinson's targets in Mission pact; Amarin files for Vascepa OK in Europe
→ Back in 2018, AbbVie teamed up with protein degradation experts at Mission Therapeutics to focus on deubiquitylating enzymes, or DUBs, to tackle Alzheimer’s and Parkinson’s disease. And today, the pact has reached its first milestone — with AbbVie choosing the panel of DUBs that will be progressed for further characterization and screening activities.
→ After emerging from an expert panel review last month with a unanimous endorsement for their fish oil-based heart drug Vascepa — boding well for their upcoming FDA review — Amarin has filed the drug for review by the EMA. The drug is already approved in the US for the treatment of elevated triglycerides, but the company is gunning to expand the label to include the reduction of the incidence of heart attack and stroke in high-risk patients.
→ Boston Biomedical, a US subsidiary of Japan’s Sumitomo Dainippon Pharma, has sealed an oncology research alliance with Columbia University, Harvard University and The Wistar Institute, gaining access to novel targets and platform technologies emerging out of the institutions over the next five years.
→ Taiwan-based Lumosa Therapeutics announced that the FDA has accepted its IND application for their analgesic injection, LT1001 — allowing for the commencement of a bridging study in the US. The drug, which contains a prodrug of nalbuphine, is pitched as an abuse-free alternative painkiller amid an ongoing opioid crisis. The company anticipates enrollment to be completed in the first half of 2020.
→ Although investors of Puma Biotechnology were left fretting as Q1 sales of Nerlynx fell short of Wall Street estimates, the company’s licensing partner Specialised Therapeutics Asia has received the greenlight to market Nerlynx in Singapore by the Health Sciences Authority (HSA). The drug is indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to be given after adjuvant therapy featuring Herceptin (trastuzumab).